Recombinant mouse monoclonal antibody raised against human PRMT3.
Original antibody is raised against recombinant protein corresponding to amino acids 211-531 of human PRMT3.
Flow Cytometry (3-5 ug x 106 cells) Immunocytochemistry (2 ug/mL) Immunofluorescence (2 ug/mL) Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) (1:20) Immunoprecipitation (2 ug) Western Blot (0.5-1 ug/mL) The optimal working dilution should be determined by the end user.
In PBS (0.09% sodium azide).
Store at 4°C. For long term storage store at -20°C. Aliquot to avoid repeated freezing and thawing.
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Western Blot analysis of Lane 1: T47D, Lane 2: A549, Lane 3: U2OS, Lane 4: K562, Lane 5: HeLa, Lane 6: Raji, Lane 7: HEK-MSR, Lane 8: MCF7, Lane 9: MDA-MB-231, Lane 10: LNCaP and Lane 11: HepG2 cell lysates with PRMT3 recombinant monoclonal antibody (Cat # RAB00246).
Immunohistochemical staining (Formalin-fixed paraffin-embedded sections) of human colon carcinoma (A) and human breast carcinoma (B) tissues (right) with PRMT3 recombinant monoclonal antibody (Cat # RAB00246) compared to a negative control without primary antibody respectively (left).
Type I protein arginine N-methyltransferases (PRMTs), such as PRMT3, catalyze the formation of asymmetric N(G),N(G)-dimethylarginine (ADMA) residues in proteins (Tang et al., 1998 [PubMed 9642256]).[supplied by OMIM